Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178838 | 0.90 | P2RY12 (0.41) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL4019016 | 0.90 | P2RY12 (0.53) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL3932846 | 0.88 | P2RY12 (0.48) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL4161313 | 0.88 | P2RY12 (0.45) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL3941379 | 0.88 | P2RY12 (0.41) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL3930122 | 0.87 | P2RY12 (0.42) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL4166675 | 0.87 | P2RY12 (0.53) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL3942186 | 0.87 | P2RY12 (0.40) | P2RY12ALDH1A1KDM4EMEN1MAPK1 | |
| SCHEMBL4174937 | 0.86 | P2RY12 (0.51) | P2RY12CHRM2CYP3A4CYP2C9DRD3 | |
| SCHEMBL3929704 | 0.86 | P2RY12 (0.41) | P2RY12ALDH1A1KDM4EMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009011627-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018166-A1 | New Pyridine Analogues X 161 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885ALDH1A1 1717/4885KDM4E 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.